Bristol

Idles’ fifth album starts with an arpeggiating piano and ends on a short, unshowy sax solo. One bouncing track, Dancer, is about the pleasure of bodies moving “cheek to cheek” and “hip to hip”; it features backing vocals by James Murphy and Nancy Whang from club-rock deities LCD Soundsystem. Another Tangk high point, the slow-burning Grace, imports the pensive synth reverberations of LCD’s track Someone Great.Given that Idles’ pulverising first three LPs were fuelled by terse menace and guitar firepower, a major shift is…

Sen. Bernie Sanders, left, appears at a news conference with Sen. Ed Markey on issuing subpoenas for pharmaceutical company CEOs to testify regarding drug prices, in the Capitol, Jan. 25, 2024.Bill Clark | Cq-roll Call, Inc. | Getty ImagesSenators will question the CEOs of Johnson & Johnson, Merck and Bristol Myers Squibb on U.S. drug prices at a hearing Thursday, as lawmakers on both sides of the aisle work to rein in high health-care costs for Americans. The push to cut drug prices is one of those rare hot-button…

The new sports streaming service from broadcast behemoths ESPN, Warner Bros. Discovery, and Fox could cost between $45 and $50, according to sources familiar with the matter who spoke with CNBC. Johnny Knoxville Loved Collectibles | First FandomsAnnounced on Tuesday, the streaming service will give fans access to each broadcaster’s catalog of sports programming, allowing them to watch a range of content from more than a dozen networks. It will be launched as a new brand with a new app in a joint venture between the three…

Bristol Myers Squibb reported quarterly earnings and revenue that topped expectations on Friday as its portfolio of new drugs posted strong sales growth. Here's what the company reported for the fourth quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG, formerly known as Refinitiv:Earnings per share: $1.70 adjusted vs. $1.53 expectedRevenue: $11.48 billion vs. $11.19 billion expectedBristol Myers, one of the world's largest pharmaceutical companies, booked $11.48 billion in revenue…

Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com. Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead. CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.It took subpoena…

The New York Stock Exchange welcomes Johnson & Johnson (NYSE: JNJ) to the podium. NYSEBig pharmaceutical companies such as Bristol Myers Squibb, Merck and Johnson & Johnson face a looming threat that will put tens of billions of dollars in sales at risk between now and 2030, as blockbuster drugs will tumble off a so-called patent cliff.That refers to when a company's patents for one or more leading branded products expire, which opens the door for competitors to sell copycats of those drugs, often at a lower…

NEW YORK (AP) — Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic, in a $14 billion deal. Bristol Myers Squibb and Karuna announced their merger agreement on Friday. The transaction, which amounts to $330 per share in cash, offers a premium of 53% over Karuna’s stock on Thursday. The deal was unanimously approved by both companies’ boards of directors. Karuna’s top asset is KarXT, an experimental antipsychotic with a…

Bristol Myers Squibb on Friday announced it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash, or $330 per share.Karuna's stock popped more than 47% on the news Friday morning, hitting around $317 a share. Bristol Myers Squibb shares rose more than 3%.The deal will help expand Bristol Myers' drug pipeline after competition from a generic offering caused demand for the company's blood cancer drug Revlimid to tumble in its third quarter.The boards of directors at both Bristol Myers and…

Depending on how the sensor is configured within an EV, third parties should be able to access the sensor's data to see how badly a battery is damaged - which would address a major complaint from insurers that they lack access to data on an EV battery's health after an accident.British battery sensor firm Metis Engineering said on Tuesday it has developed a sensor to measure electric vehicle (EV) battery health that should allow insurers to properly assess damage after…

Bristol Myers Squibb on Friday sued the Biden administration over Medicare's new powers to slash drug prices, the third such lawsuit to be filed against the program in a matter of days.The lawsuit, filed in federal district court in New Jersey, argues the Medicare negotiations violate the First and Fifth Amendments of the U.S. Constitution. Bristol Myers Squibb has asked the court to declare the program unconstitutional and prevent the Health and Human Services Department from forcing the company to enter negotiations.The…